GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Portage Biotech Inc (NAS:PRTG) » Definitions » Cyclically Adjusted Book per Share

Portage Biotech (Portage Biotech) Cyclically Adjusted Book per Share : $14.14 (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Portage Biotech Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Portage Biotech's adjusted book value per share for the three months ended in Dec. 2023 was $1.618. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $14.14 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Portage Biotech's average Cyclically Adjusted Book Growth Rate was 3.50% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 4.50% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 2.30% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -0.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Portage Biotech was 10.20% per year. The lowest was -21.20% per year. And the median was -1.20% per year.

As of today (2024-05-24), Portage Biotech's current stock price is $0.2601. Portage Biotech's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $14.14. Portage Biotech's Cyclically Adjusted PB Ratio of today is 0.02.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Portage Biotech was 3.94. The lowest was 0.02. And the median was 0.70.


Portage Biotech Cyclically Adjusted Book per Share Historical Data

The historical data trend for Portage Biotech's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Portage Biotech Cyclically Adjusted Book per Share Chart

Portage Biotech Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.00 12.15 12.00 13.02 13.88

Portage Biotech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.66 13.88 14.07 14.23 14.14

Competitive Comparison of Portage Biotech's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Portage Biotech's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Portage Biotech's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Portage Biotech's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Portage Biotech's Cyclically Adjusted PB Ratio falls into.



Portage Biotech Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Portage Biotech's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book= Book Value per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=1.618/129.4194*129.4194
=1.618

Current CPI (Dec. 2023) = 129.4194.

Portage Biotech Quarterly Data

Book Value per Share CPI Adj_Book
201403 1.324 99.695 1.719
201406 0.966 100.560 1.243
201409 0.876 100.428 1.129
201412 1.362 99.070 1.779
201503 1.286 99.621 1.671
201506 2.918 100.684 3.751
201509 2.538 100.392 3.272
201512 3.281 99.792 4.255
201603 4.052 100.470 5.220
201606 4.613 101.688 5.871
201609 18.011 101.861 22.884
201612 15.641 101.863 19.872
201703 22.860 102.862 28.762
201706 60.409 103.349 75.647
201709 90.040 104.136 111.901
201712 64.708 104.011 80.515
201803 3.427 105.290 4.212
201806 3.361 106.317 4.091
201809 3.288 106.507 3.995
201812 3.199 105.998 3.906
201903 9.180 107.251 11.078
201906 9.046 108.070 10.833
201909 8.942 108.329 10.683
201912 8.971 108.420 10.709
202003 8.785 108.902 10.440
202006 8.784 108.767 10.452
202009 8.461 109.815 9.971
202012 8.685 109.897 10.228
202103 8.395 111.754 9.722
202106 9.584 114.631 10.820
202109 9.530 115.734 10.657
202112 9.426 117.630 10.371
202203 9.080 121.301 9.688
202206 9.038 125.017 9.356
202209 10.529 125.227 10.882
202212 9.897 125.222 10.229
202303 4.319 127.348 4.389
202306 4.122 128.729 4.144
202309 3.799 129.860 3.786
202312 1.618 129.419 1.618

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Portage Biotech  (NAS:PRTG) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Portage Biotech's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=0.2601/14.14
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Portage Biotech was 3.94. The lowest was 0.02. And the median was 0.70.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Portage Biotech Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Portage Biotech's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Portage Biotech (Portage Biotech) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Clarence Thomas Building, P.O. Box 4649, Tortola, Road Town, VGB, VG1110
Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through to clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.

Portage Biotech (Portage Biotech) Headlines

From GuruFocus